



## Company Overview

CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company's Cultured Foods™ brand provides a variety of 100% plant-based food products. Committed to crafting nutritious and flavorful alternatives, Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California; Grand Junction, Colorado; and Warsaw, Poland. The Company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics. Additional information is available from OTCMarkets.com or by visiting [www.cvsciences.com](http://www.cvsciences.com).

## CV Sciences, Inc. Reports Second Quarter 2025 Financial Results

Aug 13 2025, 4:00 PM EDT

## CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025

Aug 8 2025, 5:00 PM EDT

## CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3

Jun 23 2025, 8:00 PM EDT

## Stock Overview

|            |                    |
|------------|--------------------|
| Symbol     | CVSI               |
| Exchange   | OTCQB              |
| Market Cap | 7.62m              |
| Last Price | \$0.04136          |
| 52-Week    | \$0.023 - \$0.0526 |

08/26/2025 07:49 PM EDT

## Investor Relations

[ir@cvsciences.com](mailto:ir@cvsciences.com)

## Management Team

### Joseph Dowling

Chief Executive Officer

### Joerg Grasser

Chief Financial Officer

### Jesse Karagianes

SVP, Revenue Growth

## CV Sciences, Inc.

9530 Padgett Street

Suite 107

San Diego, CA 92126

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

